Cargando…
Ranibizumab in neovascular age-related macular degeneration
Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstra...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699647/ https://www.ncbi.nlm.nih.gov/pubmed/18046922 |
_version_ | 1782168515850010624 |
---|---|
author | Eng, Kenneth T Kertes, Peter J |
author_facet | Eng, Kenneth T Kertes, Peter J |
author_sort | Eng, Kenneth T |
collection | PubMed |
description | Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration. |
format | Text |
id | pubmed-2699647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26996472009-06-23 Ranibizumab in neovascular age-related macular degeneration Eng, Kenneth T Kertes, Peter J Clin Interv Aging Reviews Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration. Dove Medical Press 2006-12 2006-12 /pmc/articles/PMC2699647/ /pubmed/18046922 Text en © 2006 Dove Medical Press Limited. All rights reserved |
spellingShingle | Reviews Eng, Kenneth T Kertes, Peter J Ranibizumab in neovascular age-related macular degeneration |
title | Ranibizumab in neovascular age-related macular degeneration |
title_full | Ranibizumab in neovascular age-related macular degeneration |
title_fullStr | Ranibizumab in neovascular age-related macular degeneration |
title_full_unstemmed | Ranibizumab in neovascular age-related macular degeneration |
title_short | Ranibizumab in neovascular age-related macular degeneration |
title_sort | ranibizumab in neovascular age-related macular degeneration |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699647/ https://www.ncbi.nlm.nih.gov/pubmed/18046922 |
work_keys_str_mv | AT engkennetht ranibizumabinneovascularagerelatedmaculardegeneration AT kertespeterj ranibizumabinneovascularagerelatedmaculardegeneration |